Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients
The most apparent 28-day all-cause mortality benefit for vilobelimab was in western Europe. Age imbalance between treatment groups in Brazil may have resulted in a lower efficacy signal for vilobelimab in South America compared with other regions. Overall, vilobelimab demonstrated a favourable safety profile and reduced mortality in critically ill, intubated COVID-19 patients, with regional variations influencing outcomes.
Authors
- Matthijs C. Brouwer (ORCID: https://orcid.org/0000-0001-7775-7843)
- Robert Zerbib
- Endry H. T. Lim (ORCID: https://orcid.org/0000-0002-7385-5929)
- Niels C. Riedemann (ORCID: https://orcid.org/0000-0002-8915-3315)
- Alexander P. J. Vlaar (ORCID: https://orcid.org/0000-0002-3453-7186)
- Sanne de Bruin (ORCID: https://orcid.org/0000-0001-9681-9325)
- Camilla Chong
- Bruce Burnett (ORCID: https://orcid.org/0000-0001-5800-6622)
- Diederik van de Beek (ORCID: https://orcid.org/0000-0002-4571-044X)
- Claus Thielert
- Renfeng Guo
- Simon Rückinger
Institutions
- Inflarx (Germany) (DE)
- Arbor Pharmaceuticals (United States) (US)
- University of Amsterdam (NL)
Publication Details
- Journal
- BMJ Open Respiratory Research
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/bmjresp-2023-002206
- Primary Topic
- Sepsis Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Australian Government
- Universiteit van Amsterdam
- InflaRx